What is ALS?

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. ALS usually affects people between the ages of 40 and 70, but this doesn’t mean that it cannot be diagnosed at other ages. Unfortunately, around 20,000 American citizens are estimated to develop the disease…

Researchers at the University of California-Riverside have shown, for the first time, that infection from the common parasite Toxoplasma gondii disrupts neurotransmitter glutamate function in the brain, potentially leading to neuronal death and neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), in individuals predisposed to such conditions. The research paper, “…

Amyotrophic lateral sclerosis (ALS) is a disease that progressively shuts down your muscles by attacking certain cells in the brain and spinal cord needed to keep our muscles moving. Eventually, patients will lose their mobility, have trouble moving, walking, swallowing and even breathing. In this video, shared by …

In this video from teleemg’s channel, watch Dr. Joe F. Jabre, neurologist, discuss some facts and useful information about amyotrophic lateral disease (ALS), also known as Lou Gehrig’s disease, such as its causes, symptoms and signs, life expectancy and how it can be…

Meet Matthew Hodge. Matthew has been diagnosed with amyotrophic lateral sclerosis, also known as ALS, and throughout the years, he has lost his ability to move or speak. However, due to the evolution of technology, he is now able to communicate with his 7-year-old son and have a chat with…

Researchers from the Institute of Drug Research at the The Hebrew University in Israel have revealed that patients with amyotrophic lateral sclerosis (ALS) have low levels of the anti-inflammatory protein alpha-1-antitrypsin (AAT) in their cerebrospinal fluid (CSF). The findings have been published in the Journal of Neuroinflammation in the study…

Rapporteurs appointed by the European Medicines Agency (EMA) have recommended that AB Science SA’s combined treatment ‘masitinib with riluzole’ in the treatment of adults with amyotrophic lateral sclerosis (ALS) should be filed for conditional marketing authorization. AB Science specializes in developing and marketing protein kinase inhibitors (PKIs), a class of targeted proteins…

A multi-disciplinary team of researchers analyzed the genotype data of thousands of ALS patients, with the objective of identifying gene variants that influence survival in ALS. The genome-wide association study identified two novel loci that significantly influence patient survival. These key findings help researchers better understand the biology of the disease…

Amyotrophic lateral sclerosis (ALS) severely burdens skeletal muscles, while eye muscles remain far less affected. Vahid M. Harandi, a doctoral student at Umea University in Sweden, and his colleagues are focusing on the specific proteins involved in both areas’ response to ALS in an effort to better understand the pathophysiology…

Over the summer and fall of 2016, 93 WALKs for ALS events will be held across Canada, organized by the Markham, Ontario-based advocacy group ALS Canada, a national organization founded in 1977 which is responsible for the ALS Canada Research Program funding peer-reviewed research grants and fostering collaboration…